ClinicalTrials.gg
Active, not recruitingNCT07219602RUBENSUpdated Sep 9, 2026

A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome

A Phase 3 interventional study of obicetrapib 10 mg + ezetimibe 10 mg FDC daily and Obicetrapib 10 mg in Lipidemia, Type 2 Diabetes (T2DM) and Metabolic Syndrome (MetS), sponsored by NewAmsterdam Pharma. Active, not recruiting at 55 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by NewAmsterdam Pharma · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 338 studies in Hyperlipidemias with a site in United States — 30 open to participants now, 45 under way, 10 of them phase 3. Hyperlipidemias · United States.

Planned enrollment
95th of 306
300 · median 120
Started
2025
with 17 others
Phase 3
73 of 338
3 open now
Primary completion
2028-03
later than 31 of 44 live
Registered
330th of 338
by date

Among the 338 studies in Hyperlipidemias with a site in United States, this one is the 95th largest by planned enrollment of the 306 interventional ones that give a count, is one of 18 that started in 2025, is one of 73 in phase 3, reaches primary completion later than 31 of the 44 other live ones, and was the 330th registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

30 of the 338 studies in Hyperlipidemias with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 338 studies in Hyperlipidemias with a site in United States, or all of them as a file.
02

Study summary

This study will be a placebo-controlled, double-blind, randomized, Phase 3 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg, both as a fixed-dose combination (FDC) with ezetimibe 10 mg and as monotherapy, on top of guideline-recommended lipid-lowering therapy in patients with metabolic syndrome and/or Type 2 Diabetes Mellitus.

03

Conditions studied

  • Lipidemia
  • Type 2 Diabetes (T2DM)
  • Metabolic Syndrome (MetS)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • fasting serum LDL-C ≥ 70 mg/dL (≥1.81 mmol/L)
  • Have fasting TG ≥150 mg/dL (≥1.7 mmol/L) and \<400 mg/dL (\<4.5 mmol/L)
  • Know diagnosis of T2DM OR have metabolic syndrome defined as fasting TG ≥150 mg/dL (≥1.7mmol/L) and \<400 mg/dL (\<4.5 mmol/L) and at least 2 risk factors
  • Are on stable guideline-recommended lipid-lowering therapy
  • Estimated ≥15 mL/min/1.73 m2

Exclusion criteria

Exclusion Criteria:

  • Have current or any previous history of class III or IV heart failure or \<30%
  • Have been hospitalized for heart failure within 5 years prior to Screening
  • Have uncontrolled severe hypertension
  • Have a formal diagnosis of homozygous familial hypercholesterolemia
  • ≥10.0% (≥0.100 fraction) or a fasting glucose ≥270 mg/dL (≥15.0 mmol/L) at Screening
  • active liver disease
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Obicetrapib/Ezetimibe

    obicetrapib 10 mg + ezetimibe 10 mg FDC daily

    Drug: obicetrapib 10 mg + ezetimibe 10 mg FDC daily

  • Experimental
    Obicetrapib

    obicetrapib 10 mg daily

    Drug: Obicetrapib 10 mg

  • Placebo comparator
    Placebo

    Placebo on top of guideline-recommended lipid-lowering therapy

    Other: Placebo

  • Experimental
    Open-Label Extension

    Open-Label Extension (OLE) with the FDC of Obicetrapib 10 mg and Ezetimibe 10 mg

    Drug: obicetrapib 10 mg + ezetimibe 10 mg FDC daily

Interventions

  • Drugobicetrapib 10 mg + ezetimibe 10 mg FDC daily

    Drug page: TA-8995

    FDC

  • monotherapy

  • OtherPlacebo

    placebo on top of guideline-recommended lipid modifying therapy

06

What researchers measure

Primary outcomes

  1. The percent change from Baseline to Day 84 in LDL-C compared with placebo for the following treatment groups: - obicetrapib 10 mg + ezetimibe 10 mg FDC treatment group; and - obicetrapib 10 mg monotherapy treatment group

    Time frame: 84 days

Secondary outcomes

  1. Percent change from Baseline to Day 84 in non-HDL-C for the obicetrapib 10 mg + ezetimibe 10 mg FDC treatment group compared with the placebo group

    Time frame: Day 84

  2. Percent change from Baseline to Day 84 in HDL-C for the obicetrapib 10 mg + ezetimibe 10 mg FDC treatment group compared with the placebo group

    Time frame: 84 days

  3. Percent change from Baseline to Day 84 in ApoB for the obicetrapib 10 mg + ezetimibe 10 mg FDC treatment group compared with the placebo group

    Time frame: 84 days

  4. Percent change from Baseline to Day 84 in ApoA1 for the obicetrapib 10 mg + ezetimibe 10 mg FDC treatment group compared with the placebo group

    Time frame: 84 days

  5. Percent change from Baseline to Day 84 in non-HDL-C for the obicetrapib 10 mg monotherapy treatment group compared with the placebo group;

    Time frame: 84 days

  6. Percent change from Baseline to Day 84 in HDL-C for the obicetrapib 10 mg monotherapy treatment group compared with the placebo group

    Time frame: Day 84

  7. Percent change from Baseline to Day 84 in ApoB for the obicetrapib 10 mg monotherapy treatment group compared with the placebo group

    Time frame: Day 84

  8. Percent change from Baseline to Day 84 in ApoA1 for the obicetrapib 10 mg monotherapy treatment group compared with the placebo group

    Time frame: Day 84

  9. Percent change from Baseline to Day 84 in lipoprotein (a) (Lp[a]) for the obicetrapib 10 mg + ezetimibe 10 mg FDC treatment group compared with the placebo group

    Time frame: Day 84

  10. Percent change from Baseline to Day 84 in Lp(a) for the obicetrapib 10 mg monotherapy treatment group compared with the placebo group

    Time frame: Day 84

Other outcomes

  1. Percent change from Baseline over time in LDL-C

    The percent change from Baseline at every visit for LDL-C

    Time frame: 40 weeks

  2. Proportion of participants that achieve LDL-C <100 mg/dL (<2.6 mmol/L), LDL-C <70 mg/dL (<1.8 mmol/L), and LDL-C <55 mg/dL (<1.4 mmol/L)

    The percent change from Baseline at every visit in the proportion of participants that achieve LDL-C \<100 mg/dL (\<2.6 mmol/L), LDL-C \<70 mg/dL (\<1.8 mmol/L), and LDL-C \<55 mg/dL (\<1.4 mmol/L)

    Time frame: 40 weeks

  3. Percent change from Baseline over time in non-HDL-C

    The percent change from Baseline at every visit for non-HDL-C

    Time frame: 40 weeks

  4. Percent change from Baseline over time in ApoB

    The percent change from Baseline at every visit in ApoB

    Time frame: 40 weeks

  5. Percent change from Baseline over time in total cholesterol

    The percent change from Baseline at every visit for total cholesterol

    Time frame: 40 weeks

  6. Percent change from Baseline over time in triglycerides

    The percent change from baseline at every visit for triglycerides

    Time frame: 40 weeks

  7. Percent change from Baseline over time in HDL-C

    the percent change from Baseline at every visit for HDL-C

    Time frame: 40 weeks

  8. Percent change from Baseline over time in Lp(a)

    the percent change from Baseline at every visit for Lp(a)

    Time frame: 40 weeks

07

Study locations

55 sites
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Mar 2028, 27 months after the start.

Of 51 industry-sponsored phase 3 interventional studies under Hyperlipidemias, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's planned 27 months is above that.

Counting every sponsor, half of 57 studies reached it within 18 months; a quarter within 11 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2025
First posted
Oct 22, 2025
StartActual
Dec 11, 2025
Primary completionEst.
Mar 2028
CompletionEst.
Jun 2028
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07219602
Lead sponsor
NewAmsterdam Pharma
Responsible party
Sponsor
First posted
Oct 22, 2025
Start date
Dec 11, 2025
Primary completion
Mar 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Sep 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TA-8995

Start the discussion